Deraphar
ActiveSummary
Deraphar has been active since 1989 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €270,143 and a net result of -€88,165. Equity is growing by about 4.1% per year across the filed financial years. Its solvency ranks better than 48% of 12,686 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Directors
Owners and capital
Owners
1 ownerChain of control
- DECURA PHARMA
- Deraphar
Highest known parent: DECURA PHARMA. The sources do not say who stands above it.
Owners 1
- DECURA PHARMAparent99.87%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.